Vitamin A supplements for preventing mortality, illness, and blindness in children aged under 5: systematic review and meta-analysis by Mayo-Wilson, Evan et al.
Vitamin A supplements for preventing mortality, illness,
and blindness in children aged under 5: systematic
review and meta-analysis
OPEN ACCESS
Evan Mayo-Wilson departmental lecturer
1, Aamer Imdad senior research officer
2, Kurt Herzer
Marshall scholar
1, Mohammad Yawar Yakoob senior research officer
2, Zulfiqar A Bhutta Noordin
Noormahomed Sheriff endowed professor and founding chair
2
1Centre for Evidence-Based Intervention, Department of Social Policy and Intervention, University of Oxford, Barnett House, Oxford OX1 2ER, UK;
2Division of Women and Child Health, Aga Khan University Hospital, Stadium Road, PO Box 3500, 74800 Karachi, Pakistan
Abstract
Objective To determine if vitamin A supplementation is associated with
reductions in mortality and morbidity in children aged 6 months to 5
years.
Design Systematic review and meta-analysis. Two reviewers
independently assessed studies for inclusion. Data were double
extracted; discrepancies were resolved by discussion. Meta-analyses
were performed for mortality, illness, vision, and side effects.
Data sources Cochrane Central Register of Controlled Trials (CENTRAL)
in the Cochrane Library, Medline, Embase, Global Health, Latin American
and Caribbean Health Sciences, metaRegister of Controlled Trials, and
African Index Medicus. Databases were searched to April 2010 without
restriction by language or publication status.
Eligibility criteria for selecting studies Randomised trials of synthetic
oral vitamin A supplements in children aged 6 months to 5 years. Studies
of children with current illness (such as diarrhoea, measles, and HIV),
studies of children in hospital, and studies of food fortification or β
carotene were excluded.
Results 43 trials with about 215 633 children were included. Seventeen
trials including 194 483 participants reported a 24% reduction in all cause
mortality (rate ratio=0.76, 95% confidence interval 0.69 to 0.83). Seven
trials reported a 28% reduction in mortality associated with diarrhoea
(0.72, 0.57 to 0.91). Vitamin A supplementation was associated with a
reduced incidence of diarrhoea (0.85, 0.82 to 0.87) and measles (0.50,
0.37 to 0.67) and a reduced prevalence of vision problems, including
night blindness (0.32, 0.21 to 0.50) and xerophthalmia (0.31, 0.22 to
0.45). Three trials reported an increased risk of vomiting within the first
48 hours of supplementation (2.75, 1.81 to 4.19).
Conclusions Vitamin A supplementation is associated with large
reductions in mortality, morbidity, and vision problems in a range of
settings, and these results cannot be explained by bias. Further placebo
controlled trials of vitamin A supplementation in children between 6 and
59 months of age are not required. However, there is a need for further
studies comparing different doses and delivery mechanisms (for example,
fortification). Until other sources are available, vitamin A supplements
should be given to all children at risk of deficiency, particularly in low
and middle income countries.
Introduction
VitaminAreferstoasubclassofretinoicacids
1longunderstood
to help regulate immune function and to reduce morbidity of
infectious diseases.
2 Vitamin A is required for normal
functioning of the visual system, maintenance of cell function
for growth, epithelial integrity, production of red blood cells,
immunity, and reproduction.
3 Different forms of vitamin A
include β carotene, which is found in plants, and preformed
vitamin A, which is found in animal sources. Vitamin A is an
essential nutrient that cannot be synthesised so it must be
obtained through diet.
1
Vitamin A deficiency increases vulnerability to a range of
illnesses including diarrhoea, measles, and respiratory
infections.
3 4 These are leading causes of mortality among
children in low and middle income countries,
5 where risk of
infectionandriskofmortalitycanbecompoundedbycoexisting
undernutrition.
6ThebioavailabilityofprovitaminAcarotenoids
in fruit and vegetables is lower than once believed,
7 8 and it is
difficult for children to fulfil their daily requirements through
plant foods alone. Consequently, vitamin A deficiency is
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Research
RESEARCHcommonamongchildrenwhosefamiliescannotaffordeggsand
dairy products.
Preformed vitamin A (retinol, retinal, retinoic acid, and retinyl
esters) is the most active in humans; it is usually used in
supplements in the form of retinyl esters.
1 3 High intake of
syntheticvitaminAoveraprolongedperiodcanleadtotoxicity,
9
buttoxicityfromfoodsourcesisrare.Periodicsupplementation
should not cause serious adverse effects.
10
Previous meta-analyses suggested that vitamin A
supplementation for children in developing countries is
associatedwithupto30%reductionsinmortality,
11-13especially
deaths from diarrhoea and measles. The World Health
OrganizationhaslongrecommendedvitaminAsupplementation
for children aged under 5 and for pregnant and breastfeeding
mothers.
14 The Countdown to 2015 identified 68 “priority
countries” in which over 90% of the world’s maternal and
childhood deaths occur
15; the programme aims to hold
governmentsaccountablefortheircommitmentstoMillennium
Development Goals. Vitamin A is now being provided in many
low and middle income countries with coverage rates of 86%.
15
Nonetheless, some critics have questioned the value and
effectiveness of vitamin A supplementation programmes, and
several studies have been conducted since initial
recommendations were made.
16 17
We undertook a review to synthesise all available evidence for
vitaminAsupplementationinchildrenaged6monthsto5years,
addingtopreviousreviewsbyinvestigatingeffectsonmortality
and the illnesses that lead to death. By investigating all effects
in the same review, we provided current estimates of treatment
effectsandidentifiedpotentialpathwaysthroughwhichvitamin
Asupplementationmightreducemortality.Acompleteprotocol
waspeerreviewedandpublishedbytheCochraneCollaboration,
and the review is available in the Cochrane Library.
18
Methods
We evaluated the effect of prophylactic synthetic oral vitamin
Asupplementationcomparedwithnotreatmentorplacebo.We
planned to conduct five subgroup analyses:
• Dose: WHO recommended dose (up to 100 000 IU for
children aged 6-11 months and 200 000 IU for children
aged 1-5 years) v lower and higher doses
• Frequency: high (doses within 6 months) v low (1 dose or
≥6 month interval)
• Location: by continent
• Age: 6-12 months v 1-5 years
• Sex: boys v girls.
Eligibility criteria
Types of trials—Randomised controlled trials including cluster
trialsandfactorialtrialswereincludedirrespectiveofpublication
status or language.
Typesofparticipants—Atthetimeofrecruitment,childrenhad
tobeaged6monthsto5yearsandapparentlyhealthy.Children
in hospital at the time of recruitment were excluded.
Types of interventions—Included studies examined synthetic
oral vitamin A supplementation compared with no treatment or
placebo, irrespective of dose or frequency. Studies of food
fortification and β carotene supplementation were excluded as
their effects can differ.
Types of outcome measures
Primary—We examined all cause mortality at the longest
follow-up. We also analysed outcomes within the first year and
more than one year after supplementation.
Secondary—We analysed cause specific mortality from
diarrhoea, lower respiratory tract infection, measles, and
meningitis. We compared the incidence and prevalence of
diarrhoea, lower respiratory tract infection, measles, malaria,
meningitis, Bitot’s spots, night blindness, and xerophthalmia.
Adverse events were noted and analysed when possible
(vomitingandbulgingfontanelle).Finally,weexaminedvitamin
A status (serum retinol) as a continuous and dichotomous
outcome.
Search strategy
WesearchedtheCochraneCentralRegisterofControlledTrials
(CENTRAL2010,issue2),Medline(seebox),Embase,Global
Health, Latin American Database (LILACS), metaRegister of
Controlled Trials, and African Index Medicus (see appendix 1
on bmj.com). All searches were conducted on 27 April 2010.
To identify ongoing and unpublished trials, we used the WHO
international clinical trials registry, which searches multiple
trial registries. Reference lists of reviews, included studies, and
excluded studies were searched for additional citations. We
contactedorganisationsandresearchersbyemailandbyphone.
Two authors (from AI, KH, and MYY) independently screened
abstracts and resolved differences with a third author (EMW).
Assessment of bias
Studies were assessed with the Cochrane Collaboration’s risk
ofbiastool.
19Twoauthorsratedeachstudyforriskofbiasfrom
sequencegeneration(wasthemethodtrulyrandom?),allocation
concealment (before enrolment, were participants’ group
assignmentsdisguised?),blindingofparticipants,assessors,and
providers (was assignment adequately disguised after
randomisation?),selectiveoutcomereporting(werealloutcome
measuresreported?),andincompletedata(dotheresultsaccount
for all participants randomised?). Risk of bias for each domain
was rated as high (seriously weakens confidence in the results),
low (unlikely to seriously alter the results), or unclear.
Discrepancies were resolved through discussion. The primary
analysis was repeated without studies at high risk of bias for
sequence generation.
Data management
Two independent people, at least one of whom was an author,
completeddataextractionandassessmentsofriskofbiasonline
with Distiller software.
20 We collected data on the time points
and measures (both collected and reported) and recruitment,
inclusion/exclusion criteria, co-interventions, dose, frequency,
duration, age, sex, setting, and location.
Statistical analysis
For continuous outcomes, we calculated the standardised mean
difference, Hedges’ g.
21 For dichotomous outcomes, we
calculated an overall risk ratio. For incidence data, risk ratio
(events per child) and rate ratio (events per child year) were
combined because these ratios use the same scale and can be
interpreted in the same way for these studies (the duration of
studies was short and there was no interaction between the
intervention and time at risk). All outcomes are reported with
95% confidence intervals, and overall effects are weighted by
the inverse of variance with a fixed effect model. In the case of
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RESEARCHSearch strategy for Medline
Medline (1950 to April (week 2) 2010)
1. exp infant/ or exp child/ or exp child, preschool/
2. (baby or babies or infant$ or toddler$ or child$ or girl$ or boy$ or pre school$ or pre-school$ or preschool$).tw.
3. 1 or 2
4. exp Vitamin A/
5. (retinol$ or retinal$ or aquasol a or vitamin a).ab,ti.
6. 4 or 5
7. randomised controlled trial.pt.
8. controlled clinical trial.pt.
9. randomized.ab.
10. placebo.ab.
11. drug therapy.fs.
12. randomly.ab.
13. trial.ab.
14. groups.ab.
15. 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14
16. exp animals/ not humans.sh.
17. 15 not 16
18. 3 and 6 and 17
clusterrandomisedcontrolledtrials,weusedadjustedestimates
reported by the authors. Where results did not control for
clustering, we contacted authors to request the intracluster
correlation coefficient. If authors were unable to provide this,
we used design effects calculated previously
11 to calculate it
using Cochrane methods.
19 For estimated values, we conducted
sensitivity analyses using larger and smaller design effects to
determine if the results were robust.
Missing data were noted for each outcome. When the numbers
of dropouts were not reported, we contacted the authors. When
analyses were reported for completers as well as controlled for
dropouts (for example, imputed with regression methods), we
used the latter.
Statistical heterogeneity was assessed by visual inspection of
forest plots, by performing χ
2 tests (assessing the P value), and
by calculating the I
2 statistic,
22 23 which describes the percentage
ofobservedheterogeneitythatwouldnotbeexpectedbychance.
If the P value was less than 0.10 and I
2 exceeded 50%, we
consideredheterogeneitytobesubstantial.Insubgroupanalyses,
we tested differences between groups with χ
2. To assess the
possibility of small study bias, we compared random effects
estimates with fixed effects estimates, drew funnel plots for
outcomes with 10 or more studies, and conducted a trim and
fill analysis,
24 which yields an effect adjusted for funnel plot
asymmetry. Meta-analysis was conducted with RevMan
25 and
Biostat CMA (comprehensive meta-analysis)
26 and a summary
of results was prepared with the GRADE system.
27
Results
Trial flow
We included 43 trials
28-69 reported in 90 papers; 39 (90%)
reported data that could be included in a meta-analysis (fig 1⇓).
The others reported outcomes that were not relevant to the
review
35 and data that were not available by group
43 or were
incomplete.
62 66 Post hoc, we included two studies in which
participants were assigned using quasi-random methods
(alternating assignment) as described below.
41 65
Eight trials nearly met the inclusion criteria but were excluded
because they were not randomised controlled trials,
70-73 were
designed to treat diarrhoea
74 or Bitot’s spots,
75 focused on
childrenwithHIV,
76ordidnotincludeaneligiblecomparison.
77
Two trials could not be assessed at this time. One including 36
children could not be located and is unlikely to affect the
results.
78 One completed trial, the deworming and vitamin A
(DEVTA) trial, seems likely to meet the eligibility criteria and
could be included in further updates of this review.
79 To assess
how the results of that trial could affect the conclusions of our
review, we conducted a sensitivity analysis for the primary
outcome.
Study characteristics
Trials included 215 633 participants with a median sample size
of 480, ranging from 35
66 to over 29 000.
63 The 39 trials that
wereanalysedincluded215043participants(99.8%ofchildren
included in the review).
Of the 43 included trials, 37 compared vitamin A
supplementation with placebo. Four used factorial designs,
combining vitamin A supplementation with other treatments
such as zinc
46 51 62 or deworming.
55 In one trial,
51 raw data were
not available and we could not identify outcome data for an
eligible comparison. Different doses were combined for the
main analysis in one trial.
40
The median of the mean ages was 30.5 months. Most trials
assignedequalnumbersofboysandgirls;threestudiesfavoured
boys by more than 10%.
45 54 57 When trials reported outcomes
atmultipletimepoints,weanalysedthelongestfollow-up;most
studieslastedaboutoneyear.Table1⇓describescharacteristics
for individual studies, and table 2⇓ shows counts for subgroup
characteristics.
Risk of bias
Figure 2 shows the risk of bias ratings
19 for each trial.⇓ Three
trialswereathighriskofbiasforsequencegeneration(nottruly
random), and these included 41 139 participants.
29 41 65 In two
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RESEARCHquasi-random studies (included post hoc), the authors and the
Cochrane editors agreed that the methods of assignment had
the desirable characteristics of randomisation and were at no
greater risk of bias than other included studies. Only one study
was at high risk of bias because of inadequate allocation
concealment, but concealment of the allocation sequence was
not sufficiently described in 27 trials.
Lack of blinding of assessors created a high risk of bias in only
two studies, but it was unclear if assessors were blind in 14
trials. Two studies were at high risk of bias for failing to blind
projectstaff,and13trialswereunclearonthisissue.Atthetrial
level,ninewereathighriskofbiasformissingdataand12were
unclear, though missing data for the primary outcome was not
a concern.
Only four studies seemed to be completely free from selective
outcome reporting. It was unclear if 24 trials reported all
outcomes, but the primary outcome (mortality) was known for
almostallparticipantsinthereview.Totestforbias,theprimary
analysis was repeated without studies at high risk of bias for
sequence generation.
Quantitative data synthesis
All cause mortality
Mortality (fig 3⇓) was reported in 17 trials including 194 483
children (90% of the children in the review); one reported no
events and was not analysed.
45 Thus, 16 trials were included in
the primary meta-analysis. Two studies
41 65 randomised
households, and we treated them as if they had randomised
individuals. Previously reported design effects
11 were used to
calculate intracluster correlation coefficients for six cluster
randomisedstudies.
37 52 56 63 68 69Thecoefficientswereconsistent,
and we imputed an intracluster correlation coefficient of 0.002
for all studies in which clustering was not considered in the
original analysis. A sensitivity analysis was conducted for all
cause mortality with coefficients of 0 and 0.01 for those studies
in which the mean design effect was estimated.
Vitamin A was associated with a 24% reduction in all cause
mortality (0.76, 95% confidence interval 0.69 to 0.83; fig 3),
though there was moderate heterogeneity (χ
2=29.10, df=15,
P=0.02; I
2=48%). Only five trials
36 38 48 56 68 (7% of trials)
measured mortality after 13 months, and the effect was similar
(0.75,0.64to0.88)withsubstantialandsignificantheterogeneity
(χ
2=9.29, df=4, P=0.05; I
2=57%).
We then added a study awaiting assessment to the analysis.
79 In
an analysis of 17 trials, this study (the deworming and vitamin
A trial) accounted for 65.2% of the combined effect (fig 4⇓),
whichremainedsignificant(0.88,0.84to0.94)withsubstantial
and significant heterogeneity (χ
2=44.31, df=16, P<0.001;
I
2=64%). Though the benefit of vitamin A decreased by half
(24% to 12%), the result remained clinically important. As we
were unable to assess the trial, we cannot explain this
substantially different result; its impacts on the conclusions of
this review are considered below.
Of those in the main analysis, 10 trials were conducted in Asia,
five in Africa, and one in Latin America. There was no clear
difference (P=0.12) between the Asia subgroup (0.69, 0.61 to
0.79) and the Africa subgroup (0.85, 0.73 to 0.98), though the
Latin American trial reported no effect (1.00, 0.14 to 7.08). We
planned to compare trials in urban and rural areas, but only two
urbantrialsreportedtheprimaryoutcome;ananalysiscomparing
1982 and 192 501 participants would be difficult to interpret.
Four trials reported separate effects for children aged 6-12
months (0.59, 0.43 to 0.82) and children aged 1-5 years (0.68,
0.57to0.82);thesubgroupsdidnotdiffersignificantly(P=0.46).
Fivetrialsreportedseparateeffectsforboys(0.80,0.66to0.97)
and girls (0.79, 0.65 to 0.95), which were not significantly
different (P=0.89). Notably, effects for sex and age subgroups
are all larger than the overall result, and these results should be
interpreted with caution.
Onlyonetrialprovidingsmallfrequentdosesreportedmortality
data, and the effects were larger (0.46, 0.30 to 0.71) than the
effects for the WHO recommended dose delivered every four
to six months (0.81, 0.72 to 0.90) or the recommended dose
delivered once (0.66, 0.52 to 0.83). Differences between
subgroupsweresignificant(P=0.02),butonlythegreatereffect
for small frequent doses seems clinically plausible (fig 5⇓).
Of the trials at high risk of bias from sequence generation, only
one contributed to primary analysis, and it reported no effect
(1.06, 0.82 to 1.37), indicating that these trials were not likely
to inflate the combined effect.
Theprimaryanalysiswasrepeatedwitharandomeffectsmodel,
and the overall estimate was slightly larger; thus, heterogeneity
is partially explained by small studies reporting larger effects
(0.71, 0.61 to 0.84), which could be related to bias or to clinical
differences (such as better implementation in small trials). We
drew a funnel plot and conducted a trim and fill analysis (fig
6⇓). There was some evidence of asymmetry (five studies
trimmed), but the overall effect was strongly influenced by five
studies that accounted for over 80% of the weighted mean, and
there was no effect of replacing missing studies (adjusted value
rate ratio=0.80, 0.73 to 0.87).
We also conducted a sensitivity analysis to determine if the
intraclustercorrelationcoefficientsusedtoadjustforclustering
influenced the overall effect. The size of the effect was slightly
smallerwhenthesetrialsweretreatedasiftheyhadrandomised
individuals (0.81, 0.75 to 0.89) and was unchanged when we
increased the coefficient to 0.01 (0.75, 0.68 to 0.83). Adjusting
three studies for which the intracluster correlation coefficients
was unknown did not affect our conclusions; further inflating
theirstandarderrorswouldincreasethesizeoftheoveralleffect.
Cause specific mortality
VitaminAsupplementationwasassociatedwitha27%reduction
in deaths from diarrhoea. Differences in deaths from measles
and meningitis were not significant (table 3⇓).
Morbidities
Morbidity was measured in different ways, and we combined
allavailabledatawheneverpossible.Forexample,fordiarrhoea
weincludedalltypesofdiarrhoea(mild,moderate,andsevere).
Pneumoniaandlowerrespiratorytractinfectionoutcomeswere
combined post hoc because pneumonia is a type of lower
respiratory tract infection and many studies did not have
complete diagnostic information.
Overall, there was a 15% decrease in diarrhoea incidence (fig
7⇓) and a 50% decrease in incidence of measles (fig 8⇓);
heterogeneity in the former analysis was substantial, but
heterogeneity in the second was not important. Only one trial
reported incidence of malaria, which showed a reduction, and
effectsonlowerrespiratoryinfectionswerenotsignificant(table
3⇓). Few studies reported prevalence data; results for diarrhoea
and malaria were not significant, and there were no data for
measles.
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2011;343:d5094 doi: 10.1136/bmj.d5094 Page 4 of 19
RESEARCHVision
Evidence for vision outcomes was based on a small number of
small studies. The available studies suggest a large reduction
in the incidence and prevalence of night blindness and a large
reduction in the prevalence of xerophthalmia, but effects on
Bitot’s spots and the incidence of xerophthalmia were not
significant (table 4⇓).
Vitamin A deficiency
Serumconcentrationsweremeasuredinasmallnumberofsmall
studies. These suggest that vitamin A supplementation reduces
the proportion of children who are deficient and increases
vitamin A serum concentrations (table 4⇓), but heterogeneity
was substantial. These results could be influenced by bias, and
serum concentrations might be a poor indicator of vitamin A
status.
Adverse events
Three trials reported that high doses of vitamin A triple the risk
of vomiting within 48 hours. Results for fontanelle side effects
were not significant in one study (table 4), and two studies that
measured the outcome could not be analysed.
Discussion
Comparable with previous reviews, this review shows that
vitamin A supplementation is associated with large and
importantreductionsinmortalityforchildreninlowandmiddle
incomecountries.Thisaddssubstantivelytopreviousreviews
11-13
in providing a plausible pathway and indicating that vitamin A
supplementation reduces the incidence of and mortality from
diarrhoea and measles. Vitamin A also reduces precursors to
blindness. While there was a slight increase in the risk of
vomiting within 48 hours, there was no evidence of serious
adverse events as a result of periodic supplementation. Most
trials did not measure vitamin A serum concentrations at
baseline as children are unlikely to experience serious harm
under these conditions; continuous supplementation, however,
might lead to toxicity and cause more severe side effects. It is
unclear if smaller more frequent doses would lead to the same
minor side effects observed in this review.
9
Vitamin A deficiency is common during childhood in many
low and middle income countries, even among populations
whose diets rely heavily on vegetables and fruits.
80 The reasons
are multiple and include widespread maternal undernutrition,
poor dietary quality, and losses during diarrhoea.
81 82 WHO
estimates that 122 countries have a moderate to severe public
health problem.
83
Strengths and limitations
For the primary outcome, the evidence in this review is strong.
Sixteen studies were analysed, which included a large number
of children. Subgroup and sensitivity analyses show that the
result is robust and the effects of bias were not important.
Fortheprimaryoutcome,thequalityoftheevidencewas“high”
on the GRADE scale
27—that is, further trials are unlikely to
change the conclusion that vitamin A supplementation has a
large and significant effect (table 3). It seems unlikely that the
primary outcome is significantly overestimated because of bias
from any source. Almost all studies were randomised with
appropriate methods for sequence generation, and allocation
was well concealed. It was easy to blind participants and
providers, and most trials reported that people were unaware of
the treatments being provided. Furthermore, lack of blinding
might underestimate rather than overestimate effects—for
example, a teacher might give extra food to a child receiving a
placebo. Failure to blind assessors is unlikely to influence
mortality data. Risks of selective outcome reporting and
publication bias are low; the primary analysis included nearly
all participants who had been randomised, and all studies large
enoughtomakeadifferenceinthisanalysisareprobablyknown.
Two trials at high risk of bias for sequence generation were
includedposthoc,butstepstomaintainallocationconcealment
and blinding minimised the possibility that participants were
treateddifferentlybetweengroups.Inthefirst,participantswere
assigned alternately by household.
41 The second used a random
starting point and alternating distribution of red or green pills;
the manufacturer held the code until the study was completed.
65
Thedecisiontoincludethesestudieswasmadebeforedatawere
extracted, and the one study that contributed to the primary
outcome
41 reported no effect (1.06, 0.82 to 1.37). The decision
to include these studies did not result in an overestimation of
the primary outcome.
This review makes an important contribution by identifying
several pathways though which vitamin A could reduce
mortality. Much of the reduction in all cause mortality is
probably explained by reductions in death from diarrhoea and
measles, which are leading contributors to child mortality in
low and middle income countries.
5 This hypothesis is
strengthened by a review indicating that vitamin A
supplementation prevents acute diarrhoea from becoming
chronic.
84 Though the overall effect for mortality from measles
was not significant, the trend was consistent with the overall
results,andthetherapeuticeffectsofvitaminAsupplementation
for measles are well established.
78
For the secondary outcomes, the quality of the evidence was
variable on the GRADE scale (tables 3 and 4), though evidence
formeaslesincidencewashighquality.Wedowngradedratings
for diarrhoea and measles mortality to “moderate” because of
uncertainty about the size of the effects; these results are
consistent with other findings and consistent with biological
mechanisms through which vitamin A supplementation could
cause an overall reduction in mortality.
In general, large studies examined effects on mortality while
small studies measured illness, vision, and vitamin A serum
concentrations. A few studies measured growth, though we did
not include this as an outcome. Different outcomes are
appropriate for studies with different purposes, but many
secondary analyses include only a small proportion of the
participants in the review. Recent evidence suggests that the
prevalence of selective reporting of outcomes is high and that
thismightsubstantiallybiassystematicreviews.
85 86Ifoutcomes
were reported selectively, addition of unreported data might
influence the observed effects in some secondary analyses; we
have more confidence in the internal validity of the primary
outcome than the secondary outcomes.
Secondary outcomes also have less external validity than the
primary analysis, and differences in the size of included studies
couldmaskdifferencesinthesizeoftheanalyses.Forexample,
the primary analysis includes 16 trials while analyses for
incidence of diarrhoea and serum concentration include 12 and
13 trials. Only five trials appear in both the primary analysis
and the diarrhoea analysis, and only three appear in both the
primary and serum analyses. While the primary outcome
includes 194 483 participants (90% of those randomised), the
analysis of incidence of diarrhoea includes only 37 710 (17%)
and the serum analysis includes 6623 (that is, less than 3% of
participantsinthereview).Todrawattentiontothesedifferences
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87
Comparison with earlier reviews
Landmark reviews of vitamin A for children appeared in
1993.
11 13 Since then, nine studies contributing 30% of the
childreninthisreviewhaveimprovedthequalityoftheevidence
for vitamin A supplementation in children aged under 5 years.
For the primary outcome, we conducted a cumulative
meta-analysis (fig 9⇓) to show how the effect has shifted with
the addition of studies over time. That is, each point on the plot
shows the combined effect of the new study and all studies
reported before it, and the weight is the combined weight of all
studies up to that time. Eight trials were included in a 1993
review,
11 which reported a 23% reduction in all cause mortality
(0.77,0.70to0.86).Eighttrialswereaddedtothisanalysis(one
additionaltrialreportednoevents),andtheoverallestimatehas
changedby1%.Theoveralleffectisnotmeaningfullydifferent
from the result of the first trial published in 1986. Therefore,
this review confirms that previous estimates remain valid,
finding little evidence of secular trends.
Supplementation in other populations is more controversial. A
recent review of vitamin A supplementation for children aged
under6monthsfoundnooveralleffect,butdifferencesbetween
regional subgroups might have been important.
88
Comparison with the deworming and vitamin
A (DEVTA) trial
Themostimportantqualificationofthesefindingsisthatalarge
study, awaiting assessment, found no benefit of vitamin A
supplementation.Somereviewshavefoundonlyfairagreement
between the results of meta-analyses and the results of large
trials
89; in extreme cases, large trials might indicate that the
combined results of smaller trials are incorrect in magnitude or
direction.
90Whentheresultsoflargetrialsdifferfromtheresults
ofsmalltrials,commonlyusedmethodsformeta-analysiscould
be inappropriate.
91 All things being equal (such as risk of bias
and implementation), researchers and clinicians have been
advised to trust large simple trials rather than meta-analyses of
small trials.
92 93
The deworming and vitamin (DEVTA) trial is the largest
randomised controlled trial ever conducted, including about a
millionchildrenin72clusters,morethanfourtimesthenumber
of children in this review. The trial registration describes a
factorial study comparing deworming and vitamin A, which
wasdeliveredeverysixmonthsfortwoyears.
79Thestudybegan
in 1999 and recruitment closed in 2004. The authors were
contacted several times before our review was completed, but
theydidnotprovideinformationabouttheconductofthestudy.
We are unaware of any published results. We were therefore
unabletoassesseligibility,potentialriskofbias,implementation
oftheintervention,orthegeneralisabilityofresults.Theauthors
did provide an early analysis of the primary outcome (rate
ratio=0.96, 0.89 to 1.03), as well as analyses of cause specific
mortality and vitamin A serum concentration.
DetailsthatmightexplaindifferencesbetweenDEVTAandour
reviewwerenotavailable,butwefinditunlikelythattheresults
ofourreviewcanbeexplainedbysmallstudybias.Smallstudies
could differ from mega-trials, but five trials in this review
included more than 20 000 participants and nine included more
than 10 000 participants. Furthermore, when the mortality data
forDEVTAareincluded,resultsoftheprimaryanalysisremain
significant with a fixed effect model, and that effect remains
clinically meaningful.
Heterogeneity
Statistical heterogeneity suggests there might be differences in
the effects of vitamin A supplementation across settings and
populations, and we conducted prespecified subgroup analyses
for all analyses with 10 or more studies.
Trials were conducted in 18 countries. As described above,
vitamin A supplementation was associated with significant
reductions in mortality in both Asia and Africa. While the
difference between subgroups for the primary outcome was not
significant,biochemicalconcentrationsofvitaminAseemlower
in Asia than in Africa,
83 and our results are consistent with the
hypothesis that the benefits of supplementation in Asia might
be greater.
94
For ethical reasons, some trials provided supplements to all
childrenwithsymptomsofvitaminAdeficiency(suchasBitot’s
spots).Exclusionofsuchchildrenlimitsthemagnitudeofeffects
on vision outcomes, and such restrictions could contribute to
observed heterogeneity across other outcomes in this review.
Universal supplementation could result in larger benefits than
those reported here.
A non-representative subset of studies reported data by age and
sex, but these comparisons cannot be interpreted meaningfully
except insofar as vitamin A supplementation was associated
with significant reductions in mortality for all subgroups. All
studies reporting the primary outcome used the standard dose
recommended by WHO (table 2), except for one.
52 While
differencesbetweenthesesubgroupsweresignificant,theresults
might be a statistical artefact; it is possible that small frequent
doses will lead to large reductions in mortality, but it seems
unlikelythatasinglesupplementismoreeffectivethanmultiple
supplements of the same dose.
Though we did not find evidence of specific contributors to
heterogeneity in this review, effects might differ according to
baseline vitamin A status, the availability of other nutrients, or
the prevalence of disease—for example, concomitant nutrient
deficiencies could impair the bioavailability of vitamin A
supplementation
95 and differences in the prevalence of
pathogens, sanitation, immunisation, and access to healthcare
could affect the relative impact of vitamin A supplementation.
Heterogeneity might be related to differences in the
implementation of interventions, details of which are routinely
under-reported in trials.
96 For example, it is essential that
providersdistributecapsuleseffectively,thatcapsuleshavebeen
stored properly and remain active, and that children ingest the
supplements.
Subgroup analyses in this review were limited by the available
data,andmeta-analysesofgroupleveldatatoexploreindividual
level moderators should be interpreted with caution. Further
analyseswithindividualpatientdatafromrandomisedcontrolled
trials and observational studies would be more informative.
Implications for policy
Vitamin A deficiency is a common condition that contributes
to illness, blindness, and death; supplements can reduce these
problems for children aged under 5 in low and middle income
countries. National and regional supplementation programmes
could be among the world’s most cost effective public health
interventions.
97 If the risk of death for 190 million children
deficient in vitamin A were reduced by 24%, estimates from
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98
and 20 million disability adjusted life years would be gained.
99
AlthoughvitaminAsupplementationhasbeenavailableinmany
countries for over a decade, direct evidence for its contribution
to reducing child mortality is not available. Many countries
have experienced significant reductions in child mortality,
5 100
and vitamin A supplementation programmes might have
contributed to these declines.
Supplementation responds to an immediate need, but, in the
long term, good nutrition requires reliable access to various
fresh foods. Fortification, food distribution programmes, and
horticultural developments might provide more permanent
solutions. For example, growers could increase access to
agricultural products like the orange fleshed sweet potato.
101
Vitamin A could be added to rice, though fortification
programmes must minimise risk of toxicity. Until such long
term solutions are in place, supplementation should continue.
AsaccesstovitaminAincreases,itwillbeimportanttocontinue
to identify at risk groups and to deliver supplements to them.
Ourreviewsuggestspotentialpathwaysthroughwhichvitamin
A supplementation reduces mortality. Increased vaccination
against measles and other diseases will reduce the effect of
vitamin A supplementation if its primary effect is to prevent
infection; widespread supplementation, however, will remain
important because vitamin A affects other systems—for
example, supplementation can prevent blindness.
Based on these results, we strongly recommend vitamin A
supplementation for children aged under 5 in areas at risk of
vitamin A deficiency. Despite widespread efforts, vitamin A
programmes do not reach all children who could benefit.
15
Universal distribution could be achieved in several ways.
Vitamin A supplementation can be provided when children
receiveotherserviceslikevaccinations,
102anditcanbeprovided
on a large scale. Child health days or other strategies might be
used to increase awareness,
103 and vitamin A uptake could be
increased through national food programmes
104 or through
delivery by community health workers.
105
Implications for future research
The effectiveness of vitamin A supplementation is so well
established that further placebo controlled studies are not
required. Nevertheless, this review does not identify the most
effective dose or frequency of delivery. Large doses in the
included studies were effective. Smaller, more frequent doses
might produce larger reductions in mortality; more complex
and burdensome programmes, however, could result in lower
coverage. We suggest that policymakers consider including
trials of dose and frequency in vitamin A distribution
programmes. Other studies might investigate different delivery
channels, including food supplementation, horticultural
innovations, improved access to food, or psychosocial
programmes to increase uptake of foods rich in vitamin A.
Conclusions
Our review reaffirms compelling evidence that vitamin A
supplements can prevent death and illness in children aged 6
months to 5 years. Supplements are inexpensive and have few
side effects. Further trials are needed to determine the most
effective dose and frequency of supplementation, but placebo
controlled trials would be unethical. Policymakers should
continueworkingtoprovidesupplementsforallchildrenatrisk
of deficiency, particularly those in low and middle income
countries.
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Table 1| Characteristics of included studies in review of effect of vitamin A supplementation on mortality, illness, and blindness in children
aged under 5
Frequency* Dose (1000 IU)
Follow-up
(months)
No of
participants Age (months) Country Study
0, 4, 8, 12 m 50 at 1-6 m; 100 at >6 m 15, 27 17 778† 0-72 India Agarwal 1995
28
1 dose 100 24 hour 256 9-12 India Arya 2000
29
1 dose 100 4 618 6-9 India Bahl 1999
30
0, 4, 8, 12 m 100 at <12 m; 200 ≥12 m 12 1240 6-48 Brazil Barreto 1994
31
1 dose 100 12 462 6-9 Guinea Bissau Benn 1997
32
1 dose 200 6 180 12-71 India Biswas 1994
33
4, 10 m 100 at <12 m; 200 ≥12 m 12 198 6-36 China Cheng 1993
34
1 dose 100 6 395 6-9 India Cherian 2003
35
0, 5, 10 m 50 at <6 m; 100 at 6-12 m;
200 at >12m
15 1520 <120 India Chowdhury 2002
β 36
1 dose 50 at <6 m; 100 at 6-12 m;
200 at ≥12 m
5 7197† 1-59 Nepal Daulaire 1992‡
37
0, 4, 8, 12, 16, 20, 24 m 103 at <12 m; 206 at ≥12 m 24 1405 6-47 Indonesia Dibley 1996
38
0, 6, 12 m 100 at <12 m; 200 at ≥12 m 12 235 0-72 Congo (Zaire) Donnen 1998‡
39
1 dose 100, 200§ 1 week 2471 12-72 Philippines Florentino 1990
40
0, 6, 12, 18 m 200 18 28 753 9-72 Sudan Herrera 1992
41
0, 6, 12 m 200 12 267 12-54 Indonesia Kartasamita 1995
42
0, 4, 8m 100 at <12 m; 200 at ≥12 m 36 79 2-108 Brazil Lima 2010‡
43
0, 0.5, 1, 1.5, 2, 2,5, 3 m 100 3 70 24-84 China Lin 2008
45
0, 1, 2, 3 m 100 3 86 6-84 China Lin 2009
44
0, 2, 4, 6, 8, 10, 12 m 20 at <12 m; 45 at ≥12 m 12 786 6-15 Mexico Long 2006
46
0, 2, 4, 6, 8, 10, 12 m 20 at <12 m; 45 at ≥12 m 12 195 6-15 Mexico Long 2007
47
1 dose 100 at 6-12 m; 200 at ≥12 m 24 25 301† 6-120 Nepal Pant 1996‡
48
3/week for 20 weeks 3.9 20 weeks 147 1-48 Australia Pinnock 1986
49
Weekly for 1 year 14 12 206 0-24 Australia Pinnock 1988
50
1 dose 200 6 800 12-35 Bangladesh Rahman 2001
51
Weekly for 1 year 8.333 12 15 419† 6-60 India Rahmathullah 1990
52
0, 4, 8, 12 m 100 at <12 m; 200 at ≥12 m 12 583 6-36 India Ramakrishnan 1995
53
1 dose 200 6 61 12-60 India Ranjini 2001
54
1 dose 200 12 487 12-60 India Reddy 1986
55
0, 4, 8, 12 m 100 at 6-12 m; 200 at ≥12 m 12 1455 6-59 Ghana Ross 1993 health
56
0, 4, 8, 12, 16, 20, 24 m 100 at 6-12 m; 200 at ≥12 m 12 21 906† 6-90 Ghana Ross 1993 survival
56
1 dose 200 1 236 36-72 Indonesia Semba 1992
57
1 dose 100 6 336 6 Indonesia Semba 1995
58
Weekly for 40 w 10 9 400 6-36 Ecuador Sempertegui 1999
59
0, 4, 8, 12 m 100 at <12 m; 200 at ≥12 m 13 480 6-60 Papa New Guinea Shankar 1999
60
0, 4, 8, 12 m 200 12 306 2-54 India Sinha 1976
61
Weekly for 26 w 10 6 51 26-66 Belize Smith 1999
62
0, 6 m 200 9-13 29 236† 0-71 Indonesia Sommer 1986‡
63
0, 3 m 100 30 68 6 Guinea Bissau Stabell 1995
64
0, 4, 8 m 100 at 6-11 m; 200 at ≥12 m 12 13 651 6-83 Haiti Stansfield 1993
65
1 dose 200 4 30 37 Thailand van Agtmaal 1988
66‡
1 dose 200 6 612 6 India Venkatarao 1996
67
0, 6, 12 m 200 12 15 775† 12-60 India Vijyagharvan 1990
68
0, 4, 8, 12 m 100 at 6-11 m; 200 at ≥12 m 16 28 630† 6-72 Nepal West 1991
69
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RESEARCHTable 1 (continued)
Frequency* Dose (1000 IU)
Follow-up
(months)
No of
participants Age (months) Country Study
*Several studies did not explicitly state number of doses received. We assumed that children received doses at baseline and end point—for example, “every 4
months for 1 year” appears as 0, 4, 8, and 12 months.
†Cluster randomised.
‡Compared vitamin A with treatment as usual (control group did not receive placebo).
§Two eligible intervention groups combined for analysis.
¶Mean.
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RESEARCHTable 2| Subgroup analyses for all cause mortality at longest follow-up in studies of effect of vitamin A supplementation in children aged
under 5
Heterogeneity: I
2 (%); Q Fixed effect rate ratio (95% CI)
No (%) in primary analysis
All trials Subgroup (test for difference) Participants Trials
48%; 29.10 (P=0.02) 0.76 (0.69 to 0.83) 194 483 (90) 16 (37) 43 All studies
28-69
Location (P=0.12):
— — 194 483 (90) 16 (37) — All
59%; 9.81 (P=0.04) 0.85 (0.73 to 0.98) 52 811 (25) 5 (12) 6 Africa
33 39 41 56 64
— — 0 0 2 Australia
49 50
40%; 15.00 (P=0.09) 0.69 (0.61 to 0.79) 140 432 (65) 10 (23) 28 Asia
28-30 33-38 40 42 44 45 48 51-55 57 58 60 61 63 66-69
— 1.00 (0.14 to 7.08) 1240 (<1) 1 (2) 7 Latin America
31 43 46 47 59 62 65
Setting (NA):
— — 194 483 (90) 16 (37) — All
NA NA 1982 (<1) 2 (5) 16 (Peri)urban
29 30 32 33 35 36 42 43 45-47 49-51 54 59
NA NA 192 501 (89) 14 (33) 27 Rural
28 31 34 37-41 44 48 52 53 55-58 60-69
Dose (P=0.02):
48%; 29.10 (P=0.02) 0.76 (0.69 to 0.83) 194 483 (90) 16 (37 ) — All
0%; 2.15 (P=0.54) 0.66 (0.52 to 0.83) 33 572 (16) 4 (9) 15 WHO (single)
29 30 32 33 36 37 40 48 51 54 55 57 58 66 67
48%; 19.17 (P=0.04) 0.81 (0.72 to 0.90) 147 933 (69) 11 (26) 18 WHO (4-6m)
28 31 34 36 38 39 41-47 53 56 60 61 63-65 68 69
— 0.46 (0.30 to 0.71) 15 419 (7) 1 (2 ) 10 More frequent
44-47 49 50 52 59 62 64
Age* (P=0.46):
0.0%; 6.77 (P=0.45) 0.66 (0.56 to 0.77) 61 544 (29) 5 (12) — All
15%; 3.51 (P=0.32) 0.59 (0.43 to 0.82) 4739 (2) 4 (9) 32 6-12 months
28-32 34-39 41 44 44 46-50 52 53 56 58-61 64-65
67 69
0.0%; 2.72 (P=0.44) 0.68 (0.57 to 0.81) 56 805 (26) 4 (9) 37 12-60 months
28 31 33 34 36-57 59-66 68 69
Sex† (P=0.89):
34%; 10.69 (P=0.15) 0.80 (0.70 to 0.91) 85 568 (40) 5 (12) — All
62%; 7.79 (P=0.05) 0.80 (0.66 to 0.97) 43 567 (20) 5 (12) 43 Males
28-69
0.0%; 2.87 (P=0.41) 0.79 (0.65 to 0.95) 42 001 (20) 5 (12) 43 Females
28-69
64%; 44.31 (P<0.001) 0.88 (0.84 to 0.94) 1 194 483 (98) 17 (39) 44 With DEVTA
28-69 79
NA=not available; planned analysis not conducted; DEVTA=deworming and vitamin A trial.
*For primary outcome, trials reported mortality for children <12 months,
33 children >12 months,
64 or both.
38 53 70
†One trial reporting data by sex reported no events,
46 and four trials appear in both analysis.
38 42 64 70
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RESEARCHTable 3| Summary of pooled analyses for mortality and illness in studies of effect of vitamin A supplementation in children aged under 5
Quality of evidence
(GRADE)
Follow-up
(weeks) Heterogeneity: I
2; χ²
Rate ratio (95% CI), fixed
effect
No (%) of participants
(n=215 633)
No (%) of trials
(n=43) Outcome
Primary outcome
High 12-96 48%; 29.10 (P=0.02) 0.76 (0.69 to 0.83) 194 483 (90) 16 (37) All cause mortality
313236-39
41 45 48 52 56 63 68 69 107
Cause specific mortality
Moderate 48-104 2%; 6.12 (P=0.41) 0.72 (0.57 to 0.91) 90 951 (42) 7 (16) Diarrhoea
28 36 37 41 52 56 67
Moderate 52-104 0%; 0.40 (P=0.98) 0.80 (0.51 to 1.24) 88 261 (41) 5 (12) Measles
28 37 41 52 56
Low 48-108 0%; 0.75 (P=0.69) 0.57 (0.17 to 1.88) 41 204 (19) 3 (7) Meningitis
28 36 56
Low 48-104 14%; 7.00 (P=0.32) 0.78 (0.54 to 1.14) 90 951 (42) 7 (16) LRTI
28 36 37 41 52 56 67
Illness
Diarrhoea:
Low 24-60 95%; 217.99 (P<0.01) 0.85 (0.82 to 0.87) 37 710(17) 13 (30) Incidence
29 31 33 34 36 38 40 41
47 53 59 60 67
Very low 48 87%; 15.76 (P<0.01) 1.08 (1.05 to 1.12) 14 437 (7) 2 (5) Prevalence
35 47 65
Malaria:
Very low 52 NA 0.73 (0.60 to 0.88) 480 (<1) 1 (2) Incidence
60
Moderate 48 0%; 0.02 (P=0.88) 0.72 (0.41 to 1.28) 23 361 (11) 2 (5) Prevalence
56
Measles:
High 16-78 0%; 0.55 (0.99); 0.50 (0.37 to 0.67) 19 566 (9) 6 (14) Incidence
30-32 36 41 58
NA NA NA NA 0 (0) 0 (0) Prevalence
LRTI:
Very low 24-60 22%; 7.66 (0.26) 1.14 (0.95 to 1.37) 18 179 (8) 7 (16) Incidence
31 34 36 42 47 59 67
Very low 48 NA 0.46 (0.21 to 1.03) 786 (0.4) 1 (2) Prevalence
46
LRTI=lower respiratory tract infection.
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RESEARCHTable 4| Summary of pooled analyses for admission to hospital, vision, vitamin A deficiency, and adverse events in studies of effect of
vitamin A supplementation in children aged under 5
Quality of evidence
(GRADE)
Follow-up
(weeks) Heterogeneity: I
2; χ²
Rate ratio (95% CI), fixed
effect
No (%) of participants
(n=215 633)
No (%) of trials
(n=43) Outcome
Admission to hospital
Very low 48 NA 0.64 (0.40 to 1.02) 1185 (0.5) 1 (2) All cause
56
Very low 48 NA 0.25 (0.01 to 6.11) 198 (<1) 1 (2) Diarrhoea
34
Very low 48 NA 0.11 (0.01 to 2.06) 198 (<1) 1 (2) LRTI
34
Vision
Bitot’s spots:
Very low 72 NA 0.93 (0.76 to 1.14) 28 753 (13) 1 (2) Incidence
41
Moderate 36-96 64%; 8.25 (P=0.04) 0.45 (0.33 to 0.61) 63 278 (29) 4 (9) Prevalence
48 61 63 69
Night blindness:
Low 72 NA 0.53 (0.28 to 0.99) 28 753 (13) 1 (2) Incidence
41
Moderate 52-68 0%; 0.19 (P=0.66) 0.32 (0.21 to 0.50) 22 972 (11) 2 (5) Prevalence
63 69
Xerophthalmia:
Low 48-72 63%; 2.69 (P=0.10) 0.85 (0.70 to 1.03) 58 623 (27) 3 (7) Incidence
31 41 69
Moderate 36-64 0%; 0.22 (P=0.64) 0.31 (0.22 to 0.45) 57 866 (27) 2 (5) Prevalence
31 63 69
Vitamin A deficiency
High 24-96 78%; 13.58 (P<0.01) 0.71 (0.65 to 0.78) 2262 (1) 4 (9) Number deficient
38 54 56 60
Moderate 4-96 95%; 270.23 (P<0.01) g=0.31 (0.26 to 0.36) 6623 (3) 13 (30) Serum concentration
34 38 42
44 49 50 54-57 59 60
Adverse events
Very low 48 hours 21%; 2.53 (P=0.28) 2.75 (1.81 to 4.19) 2994 (1) 3 (7) Vomiting
29 40 61
Low 48 hours NA 5.00 (0.24 to 103.72) 885 (<1) 3 (7) Bulging fontanelle
29 30 64
NA=not available; LRTI=lower respiratory tract infection.
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RESEARCHFigures
Fig 1 Identification of studies to include in review of effect of vitamin A supplementation on mortality, illness, and blindness
in children aged under 5
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RESEARCHFig 2 Assessment of risk of bias in studies on effect of vitamin A supplementation on mortality, illness, and blindness in
children aged under 5
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RESEARCHFig 3 All cause mortality in studies on effect of vitamin A supplementation in children aged under 5
Fig 4 All cause mortality sensitivity analysis in studies on effect of vitamin A supplementation in children aged under 5,
including deworming and vitamin A (DEVTA) trial
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RESEARCHFig 5 All cause mortality by dose in studies on effect of vitamin A supplementation in children aged under 5
Fig 6 Mortality funnel plot with trim and fill in studies on effect of vitamin A supplementation in children aged under 5.
Observed=included studies. Imputed=observed effects trimmed to make funnel plot symmetrical, opposite effects imputed,
trimmed studies and imputed effects replaced
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RESEARCHFig 7 Incidence of diarrhoea in studies on effect of vitamin A supplementation in children aged under 5
Fig 8 Incidence of measles in studies on effect of vitamin A supplementation in children aged under 5
Fig 9 All cause mortality cumulative meta-analysis in studies on effect of vitamin A supplementation in children aged under
5
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RESEARCH